Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher G Goetz

Showing results (171-180 of 313) with videos related to

Pageof 32
Sort By:
Movement Disorders : Official Journal of the Movement Disorder Society|September 15, 2011
Temporal stability of the Unified Dyskinesia Rating ScaleChristopher G Goetz, Glenn T Stebbins, Ad Theeuwes, et al.
JBI Evidence Synthesis|August 27, 2021
Rating scales for medication adherence in people living with Parkinson's disease: a systematic review protocolMichelle Hyczy S Tosin, Beatriz Guitton R B de Oliveira, Christopher G Goetz, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|December 13, 2016
Gender-, age-, and race/ethnicity-based differential item functioning analysis of the movement disorder society-sponsored revision of the Unified Parkinson's disease rating scaleChristopher G Goetz, Yuanyuan Liu, Glenn T Stebbins, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|June 25, 2017
Topiramate as an adjunct to amantadine in the treatment of dyskinesia in parkinson's disease: A randomized, double-blind, placebo-controlled multicenter studyChristopher G Goetz, Glenn T Stebbins, Kathryn A Chung, et al.
Parkinsonism & Related Disorders|October 25, 2011
Subject-investigator reproducibility of the Unified Parkinson's Disease Rating ScaleSydney E Seidel, Barbara C Tilley, Peng Huang, et al.
Neurology. Clinical Practice|January 12, 2024
A Novel Home-Based Telerehabilitation Program Targeting Fall Prevention in Parkinson Disease: A Preliminary TrialMitra Afshari, Andrea V Hernandez, Jessica M Joyce, et al.
Clinical Neuropharmacology|July 15, 2004
Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study)C Warren Olanow, Philippe Damier, Christopher G Goetz, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|January 5, 2008
Placebo influences on dyskinesia in Parkinson's diseaseChristopher G Goetz, Eugene Laska, Christine Hicking, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|January 18, 2020
The Progressive Supranuclear Palsy Clinical Deficits ScaleInes Piot, Kerstin Schweyer, Gesine Respondek, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|October 15, 2013
Movement disorder society unified Parkinson disease rating scale experiences in daily living: longitudinal changes and correlation with other assessmentsAnthony E Lang, Shirley Eberly, Christopher G Goetz, et al.
Pageof 32

Showing results (171-180 of 313) with videos related to

Sort By:
Pageof 32
Movement Disorders : Official Journal of the Movement Disorder Society|September 15, 2011
Temporal stability of the Unified Dyskinesia Rating ScaleChristopher G Goetz, Glenn T Stebbins, Ad Theeuwes, et al.
JBI Evidence Synthesis|August 27, 2021
Rating scales for medication adherence in people living with Parkinson's disease: a systematic review protocolMichelle Hyczy S Tosin, Beatriz Guitton R B de Oliveira, Christopher G Goetz, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|December 13, 2016
Gender-, age-, and race/ethnicity-based differential item functioning analysis of the movement disorder society-sponsored revision of the Unified Parkinson's disease rating scaleChristopher G Goetz, Yuanyuan Liu, Glenn T Stebbins, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|June 25, 2017
Topiramate as an adjunct to amantadine in the treatment of dyskinesia in parkinson's disease: A randomized, double-blind, placebo-controlled multicenter studyChristopher G Goetz, Glenn T Stebbins, Kathryn A Chung, et al.
Parkinsonism & Related Disorders|October 25, 2011
Subject-investigator reproducibility of the Unified Parkinson's Disease Rating ScaleSydney E Seidel, Barbara C Tilley, Peng Huang, et al.
Neurology. Clinical Practice|January 12, 2024
A Novel Home-Based Telerehabilitation Program Targeting Fall Prevention in Parkinson Disease: A Preliminary TrialMitra Afshari, Andrea V Hernandez, Jessica M Joyce, et al.
Clinical Neuropharmacology|July 15, 2004
Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study)C Warren Olanow, Philippe Damier, Christopher G Goetz, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|January 5, 2008
Placebo influences on dyskinesia in Parkinson's diseaseChristopher G Goetz, Eugene Laska, Christine Hicking, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|January 18, 2020
The Progressive Supranuclear Palsy Clinical Deficits ScaleInes Piot, Kerstin Schweyer, Gesine Respondek, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|October 15, 2013
Movement disorder society unified Parkinson disease rating scale experiences in daily living: longitudinal changes and correlation with other assessmentsAnthony E Lang, Shirley Eberly, Christopher G Goetz, et al.
Pageof 32